Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Custodiol-N versus Custodiol for organ preservation in kidney, liver, and kidney-pancreas transplantation
2024-512444-29-00Phase 3Authorised
- Sponsor
- Franz Köhler Chemie
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in end-stage kidney disease (ESKD), hepatic disease and diabetes mellitus type 1 (T1D) comparing Custodiol-N preservation with Custodiol preservation (2 arms). Primary endpoints: Delayed graft function and AUC of GPT (ALT) over first 7 days. Planned start May 2019; status: authorised.
02
Drugs
histidine-tryptophan-ketoglutarate solution (modified)HTK Custodiol
03
Conditions
end-stage kidney disease (ESKD)hepatic diseasediabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-512444-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512444-29-00.